Pemetinib resistance management

Pemigatinib is an oral small molecule inhibitor of FGFR, mainly used to treat patients with advanced cholangiocarcinoma (iCCA) with FGFR2 gene rearrangements or mutations. Although pemetinib shows significant efficacy in some patients, as treatment progresses, some patients may develop drug resistance, affecting the therapeutic effect of the drug. This article will explore the resistance mechanisms and countermeasures to pemetinib.

Mechanism of resistance to pemetinib

1.FGFR2Mutation and gene amplification: The main target of pemetinib is FGFR2 (fibroblast growth factor receptor 2), which is used to inhibit its abnormal activity. In some patients, drug resistance may be related to secondary mutations or amplifications of the FGFR2 gene. FGFR2Mutations may lead to conformational changes in the receptor, reducing the affinity for pemetinib and weakening the inhibitory effect of the drug. In addition, FGFR2 gene amplification may also enhance the growth signal of tumor cells by increasing the number of FGFR2 receptors, thus overcoming the inhibitory effect of drugs.

2.Activation of compensatory pathways: When faced with FGFR inhibition, tumor cells may compensate for the function of FGFR by activating other signaling pathways. Pathways such as the MAPK pathway and the PI3K/Akt pathway may be upregulated to promote cell survival and proliferation and help tumors overcome the therapeutic effects of pemetinib. Especially during long-term treatment, tumor cells often selectively activate these alternative pathways to escape the inhibitory effects of drugs.

3. Upregulation of FGFR1 and FGFR3: In addition to FGFR2 mutation and amplification, overexpression of FGFR1 and FGFR3 may also be one of the causes of drug resistance. Research shows that high expression of FGFR1 or FGFR3 can partially compensate for FGFR2 by activating alternative fibroblast growth factor signaling pathways. function, resulting in failure of pemetinib treatment.

4.Changes in the tumor microenvironment: The tumor microenvironment may change, leading to the occurrence of drug resistance. For example, changes in tumor-associated fibroblasts and immune cells may make tumor cells more resistant to pemetinib. The presence of these cells may enhance the viability of tumor cells by secreting cytokines and growth factors.

Coping strategies for pemetinib resistance

1.Combination therapy: For drug resistance caused by FGFR2 mutations, the combination of other targeted therapies or chemotherapy may be an effective strategy. For example, combining PI3K/Akt pathway inhibitors, MEK inhibitors or immune checkpoint inhibitors may enhance the therapeutic effect and overcome resistance mechanisms. Clinical trials are investigating the effectiveness of this combination treatment.

2.SwitchingFGFRinhibitors: If resistance is found to be related to FGFR2 gene mutations or amplifications, switching to second or third generation FGFR inhibitors may be an effective solution. For example, other FGFR inhibitors such as chimetinib (Infigratinib) may produce better therapeutic effects in some patients with FGFR2 mutations.

3.Molecular targeted testing and personalized treatment: Regular molecular targeted testing, such as NGS (next generation sequencing) or FISH (fluorescence in situ hybridization), can help doctors evaluate changes in FGFR genes and other related pathways to develop personalized treatment plans. When drug resistance occurs, timely adjustment of treatment strategies based on test results is the key to improving treatment effects.

4.Targeted immunotherapy: Partially resistant patients can try targeted immunotherapy, such asPD-1/PD-L1combined use of inhibitors. This class of drugs can fight tumors by activating the immune system, thereby serving as potential treatment options for drug-resistant patients.

Although pemetinib provides significant therapeutic effects in patients with FGFR2 mutated or rearranged cholangiocarcinoma, the problem of drug resistance still exists. By identifying resistance mechanisms early and adopting effective countermeasures, such as combination therapy, replacement inhibitors, or personalized therapy, patients can still achieve further therapeutic effects. With the advancement of molecular biology and personalized medicine, overcoming drug resistance will become the key to improving the efficacy of pemetinib.